key: cord-0734985-8xiuwgrm
authors: Cappello, Maria; Busacca, Anita; Guida, Laura
title: The course of Covid 19 in Inflammatory Bowel Disease: protective role of TNF antagonists Response to: Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry
date: 2020-07-06
journal: Gastroenterology
DOI: 10.1053/j.gastro.2020.06.087
sha: b3783e134a58e35fd2fc704d7a8a3f0078a2f76f
doc_id: 734985
cord_uid: 8xiuwgrm

nan

we have read with great interest the paper by E. Brenner et al. [1] , which reports the preliminary results of an international registry of patients with inflammatory bowel disease and Sars-Cov2 infection, the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) . We acknowledge that data collection is still ongoing and that the sample size has significantly increased with 1170 patients included at the time of this writing [2] . However, we think the results deserve a few considerations: the rate of patients on anti-TNF either in monotherapy or in combination is higher than expected, being 43,4% of the studied population. On the basis of current clinical guidelines and the heterogeneity of the 33 participating centers, we would have expected a rate of patients on anti-TNFs not exceeding 30%, even in the US [3] . Possibly, patients on conventional maintenance therapy with mesalamine with Sars-Cov2 infection but with asymptomatic or mild clinical course have never been tested for Covid 19 either by naso-pharingeal swab or serological tests and subsequently have never been diagnosed. On the other hand, patients on biologics undergo a closer follow-up and are intensively tested because of the immunosuppression status. Due to selection bias, the negative role of mesalamine should be furtherly explored. The protective role of anti-TNF is convincing on the basis of the available, though still not yet fully proven, evidence on the efficacy of biologics in the cytokines storm phasis of Covid19 infection where at the same time steroids seem to be detrimental as demonstrated also with other coronavirus infections. However, the number of patients on steroids was low and IBD clinical activity was either mild or in remission. IBD activity seems to be associated with a worse outcome of Covid 19 as reported in the italian experience recently published in Gut.

In conclusion, the results of this report need to be explored in a larger sample. Anyway, we agree with the Authors that a takehome message for the clinicians caring for IBD is that the current pandemia should be a reason not to stop but to continue biologics and to be cautious in using high doses of steroids. Also, the role of other biologics like the gutselective anti-integrins or ustekinumab or JAK-inhibitors should be investigated.

Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry

SECURE-IBD Database Public Data Update

MSMarket Share and Costs of Biologic Therapies for Inflammatory Bowel Disease in the United States

Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study